Holen Sie sich die Stockscreener-App
99.26
0.81%
0.80
Vorhandelsmarkt:
99.05
-0.21
-0.21%
Schlusskurs vom Vortag:
$98.46
Offen:
$97.62
24-Stunden-Volumen:
787.44K
Relative Volume:
0.69
Marktkapitalisierung:
$24.93B
Einnahmen:
$3.26B
Nettoeinkommen (Verlust:
$-1.45B
KGV:
-16.91
EPS:
-5.871
Netto-Cashflow:
$1.18B
1W Leistung:
+0.61%
1M Leistung:
-12.02%
6M Leistung:
+14.34%
1J Leistung:
-0.49%
1-Tages-Spanne:
$97.05
$99.93
1-Wochen-Bereich:
$95.71
$102.23
52-Wochen-Spanne:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
99.26 | 24.93B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance UK
Form 4 BioNTech SE For: 25 September By Investing.com - Investing.com India
BioNTech SE (BNTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
BNTX Stock Price and Chart — NASDAQ:BNTX - TradingView
BioNTech SE (22UA.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
eBay Upgraded, Airbnb Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Sahin Ugur Sells 49,000 Shares, Retains 553,209 Shares Post-Transaction - Kalkine Media
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19 - accessnewswire.com
BioNTech's lung cancer drug outperforms chemo in clinical study - mugglehead.com
BioNTech's Oncology Credibility Test Comes Down to Four Days in Seoul () - aktiencheck.de
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BNTX Stock Quote Price and Forecast - CNN
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
BioNTech's Seoul Moment: Why One Halted Trial Hasn't Derailed the Oncology Narrative () - aktiencheck.de
BioNTech's September Crossroads: Seoul Data Readouts and Factory Decisions Will Test the Post-Trial Narrative - aktiencheck.de
BioNTech's Two-Front Battle: Legal Overhang in Europe Meets a Pivotal September for Oncology Data - aktiencheck.de
BNTX stock reacts to halted cancer trial and lower 2026 guidance - AD HOC NEWS
Zacks Investment ResearchGlobes - Globes - Israel Business News
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down - Eastern Progress
BioNTech's Leadership Exodus Looms as Vaccine Franchise Holds While Oncology Ambitions Take a Hit - aktiencheck.de
BioNTech's Split-Screen Week: A Trial Halted, a Vaccine Approved, and a Pipeline Under the Microscope - aktiencheck.de
Why is BioNTech stock down 7.8% today? - tradersunion.com
BioNTech stock tumbles 10% on cancer trial termination - Investing.com
BioNTech stock tumbles 10% on cancer trial termination By Investing.com - Investing.com South Africa
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Barchart.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FDA approves Pfizer-BioNTech COVID vaccine targeting XFG variant - investing.com
global market • stocks • Vienna Stock Exchange - wienerborse.at
Should You Buy Moderna Stock Following Its Cancer Breakthrough? - TradingView
Hershey Company Upgraded, Toast, Inc. Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):